Land: Australien
Sprache: Englisch
Quelle: Department of Health (Therapeutic Goods Administration)
lisinopril dihydrate, Quantity: 11.11 mg (Equivalent: lisinopril, Qty 10 mg)
Medis Pharma Pty Ltd
Tablet, uncoated
Excipient Ingredients: mannitol; calcium hydrogen phosphate dihydrate; pregelatinised maize starch; croscarmellose sodium; magnesium stearate; iron oxide red; iron oxide black; iron oxide yellow
Oral
30 tablets
(S4) Prescription Only Medicine
Hypertension: Lisinopril Hexal is indicated in the treatment of mild to moderate essential hypertension. It may be used alone or concomitantly with other classes of antihypertensive agents. Sufficient data have not been provided to support the use of lisinopril in severe hypertension or renovascular hypertension. Congestive heart failure: Lisinopril Hexal is also indicated in the treatment of heart failure. In such patients, it is recommended that Lisinopril Hexal be administered together with a diuretic. Acute myocardial infarction: Lisinopril Hexal is indicated for the treatment of acute myocardial infarction in haemodynamically stable patients, defined as patients who are not in cardiogenic shock and who have a systolic blood pressure greater than 100 mmHg. Lisinopril Hexal may be initiated within 24 hours of an acute myocardial infarction.
Visual Identification: LIGHT PINK, ROUND, BICONVEX SCORED TABLET; Container Type: Blister Pack; Container Life Time: 4 Years; Container Temperature: Store below 25 degrees Celsius
Registered
2002-11-25